Back to homepage

Psychiatry

Psychiatry

Drugs in Context Psychiatry welcomes a broad range of article types including original research, study protocols and review articles.

In line with the principle of providing context for healthcare professionals (HCPs) to properly inform and improve disease management in real world medicine, we especially encourage the submission of articles that provide context for trials of drug interventions in order to motivate improvements in disease management by HCPs practising medicine in the front line.

Corrigendum: Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Corrigendum: Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Authors: Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo

The authors wish to make the following corrections to their article: Sapin C, Hartry A, Kamat SA, Beillat M, Baker RA, Eramo A. Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis. Drugs in Context 2016; 5: 212301. DOI: 10.7573/dic.212301

More
Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Authors: Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo

In this analysis the authors used health economics assessment data collected during the QUAlity of LIfe with AbiliFY Maintena (QUALIFY) study, a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78–234 mg/mo), to determine the direct medical and pharmacy costs and the cost-effectiveness associated with each treatment over 6 months. The authors concluded that the analysis of data from stabilized patients with schizophrenia in the QUALIFY study indicated that AOM 400 is associated with lower health-care costs and greater effectiveness compared with PP and thus represents the economically dominant strategy.

More
Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

Authors: Michele Wilson, Benjamin Gutierrez, Steve J Offord, Christopher M Blanchette, Anna Eramo, Stephanie Earnshaw, Siddhesh A Kamat

Schizophrenia is associated with high direct healthcare costs due to progression of disease and frequent occurrence of relapses. Aripiprazole once-monthly (AOM) has been shown to reduce total psychiatric hospitalizations among patients who switched from oral standard of care (SOC) therapy to AOM. In this paper the authors report the results of an economic model study to evaluate the psychiatric hospitalization-related medical costs and antipsychotic pharmacy costs during a 6-month period before and after initiation of AOM treatment.

More
Effectiveness, tolerability and practical application of the newer generation anti-obesity medications

Effectiveness, tolerability and practical application of the newer generation anti-obesity medications

Authors: Jeffrey S MacDaniels, Thomas L Schwartz

In this paper, the authors compare the efficacy and tolerability of five newer anti-obesity medications to guide clinical decision making, examining bupropion–naltrexone combination, liraglutide, lorcaserin, orlistat, and phentermine–topiramate combination.

More
Antidepressant efficacy and side-effect burden: a quick guide for clinicians

Antidepressant efficacy and side-effect burden: a quick guide for clinicians

Authors: Daniel Santarsieri, Thomas L Schwartz

Prescribing of antidepressant treatment (ADT) for major depressive disorder (MDD) has increased substantially over the last two decades. In this paper, the authors discuss the evidence that supports the use of ADT based on FDA approvals, data from randomized controlled trials or meta-analyses and where these are not available, the authors discuss and apply theoretical pharmacodynamic principles to help guide treatment choice in MDD.

More

Resources